I. MODIFIED AGREEMENTS | |||
Company* |
Company* |
Change from original agreement | Terms/Details (Date) |
| | |||
BioDelivery |
Accentia Inc.* |
Amended deal gives Accentia worldwide rights to a topical formulation of encochleated amphotericin B; it previously had rights in the U.S. and Europe |
Accentia also paid BDSI $2.5M in a move that will decrease BDSI's royalty stream by half; under the original deal in April, BDSI was to get 12%-14% royalties (9/8) |
Evotec OAI AG |
Biogen Idec Inc. (BIIB) |
Expanded master services agreement to include the application of Evotec's EVOdevelop platform to a Biogen preclinical candidate |
Evotec will provide chemical process research and development and cGMP manufacturing services for Biogen Idec; the original deal between the companies is five years old (7/19) |
Infigen Inc.* |
Pharming Group NV (the Netherlands; OTC BB:PHGUF) |
Pharming gained worldwide, nonexclusive licenses to patents on nuclear transfer and associated technologies |
The deal replaces earlier agreements and does not include royalty provisions; Infigen relinquished claims to any milestone payments (7/14) |
StemCell |
Applied Imaging Corp. (ACIX) |
Renewed exclusive supply deal for use of StemCell's RosetteSep reagent technology |
The technology will be used to isolate circulating tumor cells in the blood of cancer patients; Applied Imaging can sell and incorporate RosetteSep products into its own products (7/20) |
Notes: | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
FSE = Frankfurt Stock Exchange, OTC BB = Over-The-Counter Bulletin Board. | |||
